Regenerative Nanomedicine: Ethical, Legal, and Social Issues

  • Linda MacDonald GlennEmail author
  • Jeanann S. Boyce
Part of the Methods in Molecular Biology book series (MIMB, volume 811)


Advances in regenerative nanomedicine raise a host of ethical, legal, and social questions that healthcare providers and scientists will need to consider. These questions and concerns include definitions, appropriate applications, dual use, potential risks, regulations, and access. In this chapter, we provide an overview of the questions and concerns and recommend proactive consideration and solutions.

Key words

Nanomedicine Regenerative medicine Regenerative nanomedicine Ethical, legal, and social issues ELSI Therapy Enhancement Alterations Health care disparities 


  1. 1.
    Goss, R.J. (1992) The natural history (and mystery) of regeneration. In: Dinsmore CE (ed.). A History of Regeneration Research. Cambridge: Cambridge University Press, 7–23.Google Scholar
  2. 2.
    Sandler, R. (2009) Nanomedicine and nanomedical ethics, American Journal of Bioethics 9(10), 16–17.CrossRefGoogle Scholar
  3. 3.
    : A new vision: A future for regenerative medicine, (2009) Department of Health and Human Services. Available at, last accessed October 23, 2009.
  4. 4.
    Daar, A.S., Greenwood, H.L. (2007) A proposed definition of regenerative medicine. Journal of Tissue Engineering and Regenerative Medicine,1, 179–84.Google Scholar
  5. 5.
  6. 6.
    Alpert, S. (2008) Neuroethics and nanoethics: do we risk ethical myopia? Neuroethics 1(1), 55–68. Available at, last accessed November 6, 2009.
  7. 7.
    Lee, K.B., Solanki, A., Kim, J.D., and Jung, J. (2009) Nanomedicine: Dynamic Integration of Nanotechnology with Biomedical Science. In Zhang, M and Xi, N: Nanomedicine, a systems approach, Pan Stanford Publishing Pte Ltd.Google Scholar
  8. 9.
    Mooney, E., Dockery, P., Greiser, U., Murphy, M., Barron V. (2008) Carbon Nanotubes and Mesenchymal Stem Cells: Biocompatibility, Proliferation and Differentiation Nano Letters 8(8), 2137–2143.Google Scholar
  9. 10.
    Stocum, D.L. (2009) Regenerative Biology and Medicine, Elsevier Press, San Diego, 28Google Scholar
  10. 11.
    Stem Cell Information. Bethesda, M.D: National Institutes of Health, U.S. Department f Health and Human Services, November 06, 2009. Available at:, last accessed November 9, 2009.
  11. 12.
    Wang, Z., Ruan, J., Cui, D. (2009) Advances and prospect of nanotechnology in stem cells. Nanoscale Res Letters, 4(7), 593–605.CrossRefGoogle Scholar
  12. 13.
    Garibaldi, S., Brunelli, C., Bavastrello, V., Ghigliotti, G., Nicolini, C. (2006) Carbon nanotube biocomptibility with cardiac muscle cells, Nanotech 17, 391–397.CrossRefGoogle Scholar
  13. 14.
    Panagiotis, G.K., Lehtolainen, P., Junemann-Ramirez, M., Garcia-Prieto, A., Price, A., Martin, J.F., Gadian, D.G., Pankhurst, A.Q., Lythgoe, M.F. (2009) Magnetic tagging increases delivery of circulating progenitors in vascular injury. JACC Cardiovascular Interventions, 2(8), 794.CrossRefGoogle Scholar
  14. 15.
    Traphagen, S., Yelick, P.C. (2009) Reclaiming a natural beauty: whole-organ engineering with natural extracellular materials, Regenerative Medicine, 4(5), 747–758CrossRefGoogle Scholar
  15. 16.
    Chang,W.C., Kliot, M., Sretavan, D.W. (2008) Microtechnology and nanotechnology in nerve repair, Neurol Res. 30, 10, 1053–62.CrossRefGoogle Scholar
  16. 17.
    Gravitz, L. (2009) Laser Show in the Surgical Suite, Technology Review, March/April 2009, MIT Press, available at, last accessed October 25, 2009.
  17. 18.
    Guo, J., Su, H., Zeng, Y., Liang, Y.X., Wong, W.M., Ellis-Behnke, R.G., So, K.F., Wu, W. (2007) Reknitting the injured spinal cord by self-assembling peptide nanofiber scaffold, Nanomedicine, 3(4), 311–21.Google Scholar
  18. 19.
    Science Daily, Nanoparticle-based Erectile Dysfunction Therapy Shows Promise, Sept. 20, 2009. Available at, last accessed October 30, 2009.
  19. 20.
    Woodrow Wilson Report, Project on Emerging Nanotechnologies. Available at, last accessed November 9, 2009.
  20. 21.
    United States Code of Federal Regulations, Part 312 and 314.Google Scholar
  21. 22.
    Jotterand, F. (Ed) (2009) Emerging Conceptual, Ethical, and Policy Issues in Bionanotechnology, 2009, Springer, 183–192.Google Scholar
  22. 23.
    U.S. Federal Food, Drug and Cosmetic Act of 1962 Section 201 (f). Google Scholar
  23. 24.
    White, G.B. (2009) Missing the Boat on Nanoethics. The American Journal of Bioethics, 9(10), 18–19. Available at, last accessed November 08, 2009
  24. 25.
    Note 1: Jesse Gelsinger was an 18 year old patient who participated in a gene therapy trial for Ornithine transcarboxylase deficiency (OTCD); he died from multiple organ failure 4 days after starting treatment. His death was believed to have been triggered by a severe immune response to the adenovirus carrier and was a major setback in gene therapy. Available at, last accessed November 08, 2009
  25. 26.
    Allhoff, F., Lin, P. (2008) Nanotechnology & Society: Current and Emerging Ethical Issues. (Dordrecht: Springer).Google Scholar
  26. 27.
    Schmidt, C.W. (2009) Nanotechnology-related environment, health, and safety research: examining the national strategy. Environ Health Perspect,117(4), A158–61. Available at, last accessed November 4, 2009.
  27. 28.
    Note 2: The Asilomar Conference on Recombinant DNA was an influential conference organized to discuss the potential hazards and regulation of biotechnology, held in February 1975 at a conference center Asilomar State Beach. A group of around 140 professionals participated in the conference to draw up voluntary guidelines to ensure the safety of recombinant DNA technology. Available at last accessed August 25, 2010.
  28. 29.
    Fredrickson, D.S. (2001) The recombinant DNA controversy: A memoir: science, politics, and the public interest 1974–1981. Washington, D.C.: ASM Press.Google Scholar
  29. 30.
    Paradise, J. (2008) Developing oversight frameworks for nanobiotechnology. Minn. J.L. Sci. & Tech. 9(1), 399–416.Google Scholar
  30. 31.
    Kristof, N. (2009) Chemicals and our health, New York Times, July 15, 2009, available at, last accessed November 5, 2009
  31. 32.
    Diamanti-Kandarakis, E., Bourguignon, J.P., Giudice, L.C., Hauser, R., Prins, G.S., Soto, A.M., Zoeller, R.T., Gore, A.C. (2009) Endocrine-disrupting chemicals: an Endocrine Society scientific statement. Endocr Rev. 30(4), 293–342.CrossRefGoogle Scholar
  32. 33.
    Jones, O.A.H., Voulvoulis, N., Lester, J.N. (2001) Human pharmaceuticals in the aquatic environment: a review. Environ Technol 22, 1383–1395.CrossRefGoogle Scholar
  33. 34.
    Stem Cell Information. Bethesda, MD: National Institutes of Health, U.S. Department of Health and Human Services, 2009, Available at, last accessed October 23, 2009
  34. 35.
    Munn, D. (2001) Moral Issues of Human Embryo Research. Science 293, 211.CrossRefGoogle Scholar
  35. 36.
    Pellegrino, E. (2000) Testimony, in National Bioethics Advisory Commission, Ethical Issues in Human Stem Cell Research, vol. III (Washington: NBAC, 2000), F-1-F-5.Google Scholar
  36. 37.
    Guenin, L. (2001) Morals and Primordials. Science 292, 1659–1660. Available at, last accessed November 6, 2009.
  37. 38.
    Brannigan, M.C. (2001) What if we assign moral status to human embryos? Genetic Eng News 12, 6.Google Scholar
  38. 39.
    Chan, S., Harris, J. (2008) Adam’s fibroblast? The (pluri)potential of iPCs. J MedEthics. 34 (2), 64–6.Google Scholar
  39. 40.
    Glenn, L.M. (2003) Biotechnology at the margins of personhood: An evolving legal paradigm, Journal of Evolution and Technology, 13, 110.Google Scholar
  40. 41.
    Ellis-Behnke, R.G., Liang, Y.X., You, S.W., Tay, D.K., Zhang, S., So, K.F., Schneider, G.E. (2006) Nano neuro knitting: peptide nanofiber scaffold for brain repair and axon regeneration with functional return of vision. Proc Natl Acad Sci USA, 103(13), 5054–9.Google Scholar
  41. 42.
    Sclabassi, R.J. (2009) Brain Implantable Computer Platforms, Presentation at Unither Technology Conference, Magog, Quebec. Available at, last accessed November 6, 2009
  42. 43.
    Kurzweil, R. (2005) The Singularity is Near: When Humans Transcend Biology, Viking Press.Google Scholar
  43. 44.
    Glenn, L.M. (2003) Biotechnology at the margins of personhood: An evolving legal paradigm, Journal of Evolution and Technology, 13, 110.Google Scholar
  44. 45.
    Glenn, L.M., Boyce, J.S. (2008) Nano­technology: Considering the Complex Ethical, Legal, and Societal Issues with Parameters of Human Performance, Nanoethics, 2, 265–275.CrossRefGoogle Scholar
  45. 46.
    McGee, E. (2009) Nanomedicine: Ethical concerns beyond diagnostics, drugs, and techniques. American Journal of Bioethics, 9(10), 14–15.CrossRefGoogle Scholar
  46. 47.
    McKibben, B.  (2003) Enough: Staying human in an engineered age, Times Books, New York.Google Scholar
  47. 48.
    McGee, E., (2007) Should there be a law: Brain chips: Ethical and policy issues. Thomas M. Cooley Law Review, 24(1), 81–97.Google Scholar
  48. 49.
    Jotterand, F. (2008) Beyond Therapy and Enhancement: The Alteration of Human Nature, NanoEthics, 2, 15–23CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2012

Authors and Affiliations

  1. 1.Alden March Bioethics Center, Albany Medical CenterAlbanyUSA
  2. 2.Computer Science and BusinessMontgomery CollegeTakoma ParkUSA

Personalised recommendations